A Randomised, Open-Label, Multicentre Phase 3 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, Velcade, and Prednisone (VcR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, VIncristine, and Prednisone (R-CHOP) in Patients with Newly Diagnosed Mantle Cell Lymphoma who are not Eligible for a Bone Marrow Transplant

Código del Ensayo: 26866138-LYM-3002
Fecha de Apertura: 23/06/2008
Responsable: Dolores Caballero


Indicación: LNH
Fármaco: BORTEZOMIB (VELCADE)
Fase: III
Promotor: J&J
Situación de Ensayo: Reclutamiento
Clinical Trial: http://clinicaltrials.gov/ct2/show/NCT00722137?term=26866138-LYM-3002&rank=1


Volver al listado